Potential Use of Mesenchymal Multipotent Cells for Hemopoietic Stem Cell Transplantation: Pro and Contra.

The potential of mesenchymal multipotent (stem) cells (MSC) to modify immune reactions and mediate hematopoiesis boosted great interest for their use in allogeneic hemopoietic stem cell transplantation. Because of MSC production of a wide range of cytokines and growth factors, these cells are included in the therapy of graft-versus-host disease (GVHD). A number of clinical studies have demonstrated safety and efficacy of MSC-based therapy in acute GVHD. Japan and some other countries approved biomedical cell products on the base of allogeneic bone marrow (BM) MSCs as medical agents for acute GVHD treatment. Besides, MSCs may form BM stroma and improve hematopoiesis. Simultaneous transplantation of hematopoietic stem cells and MSCs effectively improved engraftment and prevented GVHD in transplantation of umbilical cord blood and human leukocyte antigens-incompatible BM stem cells. The review presents the analysis of clinical studies of MSCs in allogeneic hematopoietic stem cell transplantation and discusses different approaches for improvement of MSC-based GVHD treatment and prophylaxis. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Citation

Mikhail Kiselevskiy, Raymonda Vlasenko, Vera Reshetnikova, Irina Chikileva, Irina Shubina, Evgeny Osmanov, Timur Valiev, Natalia Sidorova, Natalia Batmanova, Nara Stepanyan, Kirill Kirgizov, Svetlana Varfolomeeva. Potential Use of Mesenchymal Multipotent Cells for Hemopoietic Stem Cell Transplantation: Pro and Contra. Journal of pediatric hematology/oncology. 2021 Apr 01;43(3):90-94

Mesh Tags

PMID: 33560076

search → result